Bezlotoxumab (Zinplava)

OFFICE ADMINISTRATION [medical benefit]

Indications for Prior Authorization:

  • Indicated to reduce the recurrence of Clostridium difficile (c. difficile) infection (CDI) in patients at least 18 years of age who are receiving antibacterial drug treatment for CDI and are at a high-risk of CDI recurrence

Patients must met the following criteria for the indication(s) above:

  • Prescribed by or in collaboration with a specialist

  • Used in conjunction with antibacterial drug treatment of CDI
  • Patient has at least one risk factor for higher likelihood of recurrent CDI (e.g. those over 65 years of age, those with compromised immune systems, previous antibiotic exposure, admission to a healthcare facility, prior CDI and hypervirulent strains)

Dosing:

  • Administer Zinplava during antibacterial drug treatment for CDI 

  • Recommended dosing for Zinplava is a single dose of 10mg/kg administered as an IV infusion over 60 minutes

Approval:

  • 1 time treatment

Last review date: March 22, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar